The tweet was deleted by the author.
But we saved everything 🙂.
Solid Biosciences Inc. announced it will co-host a free community webinar with Defeat Duchenne on Wednesday, May 27, at 1:00 PM ET.
The event will cover SGT-003, Solid Biosciences Inc.'s investigational gene therapy for Duchenne muscular dystrophy, and provide updates on two ongoing Duchenne clinical trials. Attendees will have the opportunity to learn more about the company’s research approach and progress from expert presenters. The initiative reflects growing engagement between biotechs and patient communities seeking advances in rare disease treatments.
View post on X Loading...
Solid Biosciences previously announced advancements in precision gene therapy, presenting new targeting strategies at a major symposium earlier this year. The company has also initiated human trials for its SGT-212 gene therapy, which targets both neuromuscular and cardiac manifestations of Friedreich ataxia in a separate program. These developments come as Solid explores new therapeutic options in rare neuromuscular diseases.